Abbott Laboratories (ABT) operating KPIs
ABTNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 28, 2026Score 14/3036% above fair value
$106.20+1.63 (+1.56%)
Close on Oct 30, 2026Market cap $183.77BP/E 34.1Yield 2.26%
Abbott Laboratories electrophysiology Division (Volt PFA, TactiFlex Duo, EnSite X Cardiac Mapping) — Organic / Comparable Sales Growth (%) (%)
Form 8-K Quarterly Earnings Releases (Item 2.02 Revenue Tables) & Form 10-K/10-Q MD&A
Latest, Q3 2026
15.5%
Period ended Sep 30, 2026
Change on a year earlier
+1.8 pts
13.7% in Q3 2025
History
38 quarters
Since Q1 2017
Sources
38
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Electrophysiology Division (Volt PFA, TactiFlex Duo, EnSite X Cardiac Mapping) — Organic / Comparable Sales Growth (%) (%) | Year on year | Source |
|---|---|---|---|---|
| Q3 2026 | Sep 30, 2026 | 15.5% | +1.8 pts | SEC Filing (0001628280-26-066601) ↗ |
| Q2 2026 | Jun 30, 2026 | 13.4% | +3.1 pts | SEC Filing (0001628280-26-048377) ↗ |
| Q1 2026 | Mar 31, 2026 | 12.5% | +2.6 pts | SEC Filing (0001628280-26-025365) ↗ |
| Q4 2025 | Dec 31, 2025 | 12.5% | +3.7 pts | SEC Filing (0001628280-26-002982) ↗ |
| Q3 2025 | Sep 30, 2025 | 13.7% | -0.6 pts | SEC Filing (0001628280-25-045049) ↗ |
| Q2 2025 | Jun 30, 2025 | 10.3% | -6.4 pts | SEC Filing (0001628280-25-035135) ↗ |
| Q1 2025 | Mar 31, 2025 | 9.9% | -8.5 pts | SEC Filing (0001628280-25-017924) ↗ |
| Q4 2024 | Dec 31, 2024 | 8.8% | -12.4 pts | SEC Filing (0001628280-25-002092) ↗ |
| Q3 2024 | Sep 30, 2024 | 14.3% | -2.5 pts | SEC Filing (0001628280-24-042893) ↗ |
| Q2 2024 | Jun 30, 2024 | 16.7% | -0.2 pts | SEC Filing (0001628280-24-032182) ↗ |
| Q1 2024 | Mar 31, 2024 | 18.4% | – | SEC Filing (0001628280-24-016497) ↗ |
| Q4 2023 | Dec 31, 2023 | 21.2% | +16.3 pts | SEC Filing (0001628280-24-002009) ↗ |
| Q3 2023 | Sep 30, 2023 | 16.8% | +13.0 pts | SEC Filing (0001628280-23-034544) ↗ |
| Q2 2023 | Jun 30, 2023 | 16.9% | +11.9 pts | SEC Filing (0001628280-23-025156) ↗ |
| Q4 2022 | Dec 31, 2022 | 4.9% | -8.6 pts | SEC Filing (0001628280-23-001516) ↗ |
| Q3 2022 | Sep 30, 2022 | 3.8% | -5.1 pts | SEC Filing (0001628280-22-026588) ↗ |
| Q2 2022 | Jun 30, 2022 | 5.0% | -53.2 pts | SEC Filing (0001104659-22-081006) ↗ |
| Q1 2022 | Mar 31, 2022 | 16.8% | +9.7 pts | SEC Filing (0001104659-22-047560) ↗ |
| Q4 2021 | Dec 31, 2021 | 13.5% | +17.5 pts | SEC Filing (0001104659-22-007648) ↗ |
| Q3 2021 | Sep 30, 2021 | 8.9% | +6.1 pts | SEC Filing (0001104659-21-127874) ↗ |
| Q2 2021 | Jun 30, 2021 | 58.2% | +88.4 pts | SEC Filing (0001104659-21-094680) ↗ |
| Q1 2021 | Mar 31, 2021 | 7.1% | +10.0 pts | SEC Filing (0001104659-21-052205) ↗ |
| Q4 2020 | Dec 31, 2020 | -4.0% | -14.8 pts | SEC Filing (0001104659-21-007942) ↗ |
| Q3 2020 | Sep 30, 2020 | 2.8% | -10.5 pts | SEC Filing (0001104659-20-116611) ↗ |
| Q2 2020 | Jun 30, 2020 | -30.2% | -41.6 pts | SEC Filing (0001104659-20-083929) ↗ |
| Q1 2020 | Mar 31, 2020 | -2.9% | -16.0 pts | SEC Filing (0001104659-20-047187) ↗ |
| Q4 2019 | Dec 31, 2019 | 10.8% | -7.9 pts | SEC Filing (0001104659-20-005717) ↗ |
| Q3 2019 | Sep 30, 2019 | 13.3% | -6.4 pts | SEC Filing (0001104659-19-054283) ↗ |
| Q2 2019 | Jun 30, 2019 | 11.4% | -10.2 pts | SEC Filing (0001104659-19-040664) ↗ |
| Q1 2019 | Mar 31, 2019 | 13.1% | -5.5 pts | SEC Filing (0001104659-19-021809) ↗ |
| Q4 2018 | Dec 31, 2018 | 18.7% | +2.6 pts | SEC Filing (0001104659-19-002848) ↗ |
| Q3 2018 | Sep 30, 2018 | 19.7% | +9.0 pts | SEC Filing (0001104659-18-062380) ↗ |
| Q2 2018 | Jun 30, 2018 | 21.6% | +11.6 pts | SEC Filing (0001104659-18-045642) ↗ |
| Q1 2018 | Mar 31, 2018 | 18.6% | +7.7 pts | SEC Filing (0001104659-18-024701) ↗ |
| Q4 2017 | Dec 31, 2017 | 16.1% | – | SEC Filing (0001104659-18-003691) ↗ |
| Q3 2017 | Sep 30, 2017 | 10.7% | – | SEC Filing (0001104659-17-062667) ↗ |
| Q2 2017 | Jun 30, 2017 | 10.0% | – | SEC Filing (0001104659-17-045904) ↗ |
| Q1 2017 | Mar 31, 2017 | 10.9% | – | SEC Filing (0001104659-17-024344) ↗ |
Cite this data
StockData. (2026). Abbott Laboratories Electrophysiology Division (Volt PFA, TactiFlex Duo, EnSite X Cardiac Mapping) — Organic / Comparable Sales Growth (%) (%), quarterly Q1 2017–Q3 2026 [Data set]. Compiled from Abbott Laboratories SEC filings and investor materials. https://stockdatahq.com/stocks/abt/kpis/md-ep-yoy-org
See every metric in the Abbott Laboratories KPI table. Data updated Oct 29, 2026.